Optimal management of venous thromboembolism in advanced pancreatic cancer with low-molecular-weight heparin: current evidence

References

• Trousseau A. . Phlegmasia alba dolens. In: Trousseau A, editor. Clinique Medicale de l’Hotel Dieu de Paris. Paris: Ballier; 1865:654–712.
   Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722.
   PubMed Web of Science ®Google Scholar
• Shah MM, Saif MW. Pancreatic cancer and thrombosis. Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010. JOP. 2010;11(4):331–333.
   Google Scholar
• Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–490.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346.
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60–68.
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464.
   PubMed Web of Science ®Google Scholar
• Schattner A, Klepfish A, Huszar M, Shani A. Two patients with arterial thromboembolism among 311 patients with adenocarcinoma of the pancreas. Am J Med Sci. 2002;324(6):335–338.
   Web of Science ®Google Scholar
• Chang CY. Pancreatic adenocarcinoma presenting as sinistral portal hypertension: an unusual presentation of pancreatic cancer. Yale J Biol Med. 1999;72(4):295–300.
   Web of Science ®Google Scholar
• Shaw CM, O’Hanlon DM, McEntee GP. Venous thrombosis. Am J Surg. 2003;186:167–168.
   Web of Science ®Google Scholar
• Holden A, Ferrar D. Spontaneous arterial thrombosis in association with pancreatic carcinoma: diagnosis and interventional management. Australas Radiol. 1998;42(3):238–240.
   Google Scholar
• Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associates thromboembolic isk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013;160(4):530–537.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919–4926.
   PubMed Web of Science ®Google Scholar
• Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 1992;339(8807):1476.
   Web of Science ®Google Scholar
• Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999;82(2):947–952.
   PubMed Web of Science ®Google Scholar
• Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342(26):1953–1958.
   PubMed Web of Science ®Google Scholar
• Loynes JT, Zacharski LR, Rigas JR. Regression of metastatic non-small cell lung cancer with low molecular weight heparin. Thromb Haemost. 2002;88(4):686.
   Web of Science ®Google Scholar
• Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost. 2003;89(2):405–407.
   Web of Science ®Google Scholar
• Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95(6):507–512.
   PubMed Web of Science ®Google Scholar
• Kuderer NM. Low-molecular-weight heparin for venous thromboprophylaxis in ambulatory cancer patients: a systematic review meta-analysis of randomized controlled trials [abstract]. Presented at the 51st annual meeting of the American Society of Hematology; December 5-8, 2009; New Orleans, LA.
   Google Scholar
• Pelzer U, Opitz B, DEutschinoff G, et al. Efficacy of prophylactic low molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028–2034.
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer. 2012;48:1283–1292.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with Dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome trial (FAMOUS). Clin Oncol. 2004;22:1944–1948.
   Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949.
   PubMed Web of Science ®Google Scholar
• Van Doormaal F, Di Nisio M, Otten HM, et al. Randomized trial of the effect of low molecular heparin nadroparin on survival in patiebts with cancer. J Clin Oncol. 2011;29:2071–2076.
   PubMed Web of Science ®Google Scholar
• Klerk CPW, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609.
   PubMed Web of Science ®Google Scholar
• Ben-Aharon I, Stemmer SM, Leibovici L, et al. Low Molecular weight heparin (LMWH) for primary thrombo-prophylxis in patients with solid malignancies- systematic review and meta-analysis. Acta Oncol. 2014;53(9):1230–1237.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism and prophylaxis and treatment of patients with cancer: American society of Clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2041;59:7351–7356.
   Google Scholar
• NCCN https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed August 17, 2016.
   Google Scholar
• Mandala M, Falanga A, Roila F; ESMO Clinica Practice Guidelines. Management of thromboembolism (VTE) in cancer patients: ESMO Clinica Practice Guidelines. Ann Oncol. 2011;22(suppl 6):vi85–vi92.
   Web of Science ®Google Scholar